,0
zip,60064-6400
sector,Healthcare
fullTimeEmployees,50000
longBusinessSummary,"AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois."
city,North Chicago
phone,847 932 7900
state,IL
country,United States
companyOfficers,[]
website,https://www.abbvie.com
maxAge,1
address1,1 North Waukegan Road
industry,Drug Manufacturers—General
ebitdaMargins,0.50144
profitMargins,0.21999
grossMargins,0.69778997
operatingCashflow,22808000512
revenueGrowth,0.041
operatingMargins,0.35408002
ebitda,28444000256
targetLowPrice,135
recommendationKey,buy
grossProfits,38883000000
freeCashflow,19238250496
targetMedianPrice,166.75
currentPrice,150
earningsGrowth,0.261
currentRatio,0.815
returnOnAssets,0.085480005
numberOfAnalystOpinions,24
targetMeanPrice,164.45
debtToEquity,451.44
returnOnEquity,0.83115995
targetHighPrice,200
totalCash,7571999744
totalDebt,73647996928
totalRevenue,56725000192
totalCashPerShare,4.285
financialCurrency,USD
revenuePerShare,32.039
quickRatio,0.563
recommendationMean,2.2
exchange,NYQ
shortName,AbbVie Inc.
longName,AbbVie Inc.
exchangeTimezoneName,America/New_York
exchangeTimezoneShortName,EDT
isEsgPopulated,False
gmtOffSetMilliseconds,-14400000
quoteType,EQUITY
symbol,ABBV
messageBoardId,finmb_141885706
market,us_market
annualHoldingsTurnover,
enterpriseToRevenue,5.856
beta3Year,
enterpriseToEbitda,11.678
52WeekChange,0.33677924
morningStarRiskRating,
forwardEps,12
revenueQuarterlyGrowth,
sharesOutstanding,1767110016
fundInceptionDate,
annualReportExpenseRatio,
totalAssets,
bookValue,9.216
sharesShort,14233892
sharesPercentSharesOut,0.0081
fundFamily,
lastFiscalYearEnd,1640908800
heldPercentInstitutions,0.70832
netIncomeToCommon,12407000064
trailingEps,6.971
lastDividendValue,1.41
SandP52WeekChange,-0.010423481
priceToBook,16.276043
heldPercentInsiders,0.00107
nextFiscalYearEnd,1703980800
yield,
mostRecentQuarter,1648684800
shortRatio,1.68
sharesShortPreviousMonthDate,1649894400
floatShares,1765095578
beta,0.810714
enterpriseValue,332180750336
priceHint,2
threeYearAverageReturn,
lastSplitDate,
lastSplitFactor,
legalType,
lastDividendDate,1649808000
morningStarOverallRating,
earningsQuarterlyGrowth,0.264
priceToSalesTrailing12Months,4.715963
dateShortInterest,1652400000
pegRatio,5.04
ytdReturn,
forwardPE,12.5
lastCapGain,
shortPercentOfFloat,0.0081
sharesShortPriorMonth,12068291
impliedSharesOutstanding,0
category,
fiveYearAverageReturn,
previousClose,150.57
regularMarketOpen,149.52
twoHundredDayAverage,133.21605
trailingAnnualDividendYield,0.035996545
payoutRatio,0.7618
volume24Hr,
regularMarketDayHigh,150.05
navPrice,
averageDailyVolume10Day,6519560
regularMarketPreviousClose,150.57
fiftyDayAverage,157.2802
trailingAnnualDividendRate,5.42
open,149.52
toCurrency,
averageVolume10days,6519560
expireDate,
algorithm,
dividendRate,5.64
exDividendDate,1649894400
circulatingSupply,
startDate,
regularMarketDayLow,147.75
currency,USD
trailingPE,21.517715
regularMarketVolume,8247237
lastMarket,
maxSupply,
openInterest,
marketCap,267513004032
volumeAllCurrencies,
strikePrice,
averageVolume,7339244
dayLow,147.75
ask,155
askSize,1000
volume,8247237
fiftyTwoWeekHigh,175.91
fromCurrency,
fiveYearAvgDividendYield,4.27
fiftyTwoWeekLow,105.56
bid,150
tradeable,False
dividendYield,0.0375
bidSize,800
dayHigh,150.05
regularMarketPrice,150
preMarketPrice,
logo_url,https://logo.clearbit.com/abbvie.com
